Scolaris Content Display Scolaris Content Display

急性心筋梗塞に対するタンジン(中薬:中医学の薬草療法)製剤

Collapse all Expand all

Abstract

Background

Acute myocardial infarction (AMI) is the most important cause of morbidity from ischaemic heart disease, and is among the leading causes of death in the western world. Danshen, a Chinese herbal medicine, is widely used in China for treatment of several diseases, including AMI.

Objectives

To assess the effects (both benefits and harms) of danshen preparations for AMI.

Search methods

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library (issue 4, 2006), MEDLINE (1966‐2006), EMBASE (1980‐2006), and the Chinese Biomedical Database (CBM) (1982‐2006). We also handsearched 75 Chinese medical journals.

Selection criteria

Randomised controlled trials (RCTs) lasting at least 7 days were sought. Since it seemed evident that few RCTs were available, we also considered other controlled studies.

Data collection and analysis

Eligibility and trial quality were assessed by three reviewers.

Main results

Six studies comprised of 2368 participants were included. Only one trial was judged to be a genuine RCT and showed no statistically significant difference in reduction of total mortality (Peto OR 0.55, 95% CI 0.23 to 1.32), but a quasi‐RCT reported a reduced total mortality (Peto OR 0.42, 95% CI 0.23 to 0.77). Pooling these trials yielded an approximate halving of mortality in those patients treated with danshen preparations plus usual care compared with usual care alone (Peto OR 0.46, 95% CI 0.28 to 0.75).

Authors' conclusions

The evidence to support use of danshen preparations is too weak to make any judgement about its effects. Evidence from RCTs is insufficient and of low quality. The safety of danshen preparations is unproven, although some adverse events have been reported. More evidence from high quality trials is needed to support the clinical use of danshen preparations.

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.

一般語訳

急性心筋梗塞に対するタンジン(中薬:中医学の薬草療法)製剤

タンジン(中薬:中医学の薬草療法)は、中国において急性心筋梗塞の治療に、通常の西洋医学的治療と併用して広く用いられている。しかし、その使用を支持する強いエビデンスは存在せず、厳格な研究はほとんどされていない。急性心筋梗塞の治療において、タンジンの役割に関する正確なエビデンスを提供する良くデザインされ良く管理されたランダム化比較試験が必要である。